About Adel Nada MD, MS, MFPM
Dr. Adel Nada leads the development of NBS-03, NeoStem’s proprietary autologous expanded regulatory T-cell platform, in autoimmunity and allergy indications, including type 1 diabetes. Before coming to NeoStem, Dr. Nada led the clinical development of Baxter’s autologous CD34+ cell therapy for a variety of cardiovascular indications, and was responsible for the Phase 3 program in chronic myocardial ischemia. Before then, Dr. Nada led the Clinical Pharmacology Medical Department at Abbott Laboratories, which provided strategic and technical guidance to Abbott’s early clinical development pipeline across all therapeutic areas, and was responsible for the cardiac safety and clinical pharmacogenetics organizations.
In addition, Dr. Nada was the medical director for Abbott’s immunology project team developing a novel investigational agent for rheumatoid arthritis. Adel was an academic internist before joining industry, board certified in internal medicine, and has earned a Master’s degree in clinical research and pharmacology. He has completed advanced studies in pharmaceutical medicine at UCSF and University of Basel, and is an elected member of UK Faculty of Pharmaceutical Medicine of the Royal College of Physicians.
Financial Disclosures for Adel Nada MD, MS, MFPM
EndocrineWeb, a Vertical Health, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.
To help achieve this goal, EndocrineWeb requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.
The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.This author has not disclosed any realtionships